<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; prescriptions</title>
	<atom:link href="http://www.tapanray.in/tag/prescriptions/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Covid-19: Perils Of Haste In Scientific Decision-Making Process</title>
		<link>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-19-perils-of-haste-in-scientific-decision-making-process</link>
		<comments>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/#comments</comments>
		<pubDate>Mon, 31 Aug 2020 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Chlioroquine]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[haste]]></category>
		<category><![CDATA[hydroxychloroquine]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[perils]]></category>
		<category><![CDATA[plasma]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scientific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[WIP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10243</guid>
		<description><![CDATA[Multifaceted threats posed by Coronavirus to the humanity, are getting increasingly complex, every day. Currently, Covid-19 cases in India are ‘the highest that any country has ever recorded on a single day since the start of the outbreak.’ Alongside, the hopes of billions &#8230; <a href="http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescriptions in Generic Names Be Made A Must in India?</title>
		<link>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescriptions-in-generic-names-be-made-a-must-in-india</link>
		<comments>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/#comments</comments>
		<pubDate>Mon, 24 Apr 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aaadhar]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[identification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMJAY]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Surat]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8196</guid>
		<description><![CDATA[Would prescriptions in generic names be made a must in India? Yes, that’s what Prime Minister Modi distinctly hinted at on April 17, 2017, during the inauguration function of a charitable hospital in Surat. To facilitate this process, his government &#8230; <a href="http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Threats to Indian Generics: Failing in US Inspections is Just Half The Story</title>
		<link>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story</link>
		<comments>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/#comments</comments>
		<pubDate>Wed, 26 Feb 2014 09:44:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Cleveland]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[failing]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[half]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[Ohio]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Wellbutrin XL]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5027</guid>
		<description><![CDATA[At a recent event of the American Enterprise Institute, Dr. Harry Lever, a senior cardiologist at the Cleveland Clinic in Ohio, reportedly expressed his concern based on his personal experience regarding inconsistent quality among Indian generics. As a result, he requires switching patients &#8230; <a href="http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sets 2013, Dawns 2014: Top 7 Pharma Developments</title>
		<link>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=sets-2013-dawns-2014-top-7-pharma-developments</link>
		<comments>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/#comments</comments>
		<pubDate>Mon, 30 Dec 2013 23:20:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[back]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crystal]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Gazing]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[heralds]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Looking]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recounts]]></category>
		<category><![CDATA[revoke]]></category>
		<category><![CDATA[salient]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[Seven]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4721</guid>
		<description><![CDATA[Wish You Good Health, Happiness, Success and Prosperity in 2014 In this article I shall focus on &#8216;Top 7 Pharma Developments’, both while ‘Looking Back to 2013&#8242; and also during my ‘Crystal Gazing 2014&#8242;. Looking Back to 2013: While looking &#8230; <a href="http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>No More Payment for Prescriptions: Pharma at A Crossroads?</title>
		<link>http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=no-more-payment-for-prescriptions-pharma-at-a-crossroads</link>
		<comments>http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/#comments</comments>
		<pubDate>Mon, 23 Dec 2013 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[charitable]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[codes]]></category>
		<category><![CDATA[COI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rep]]></category>
		<category><![CDATA[rot]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[stem]]></category>
		<category><![CDATA[sunshine act]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[valsatran]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4636</guid>
		<description><![CDATA[“ARE there different and more effective ways of operating than perhaps the ways we as an industry have been operating over the last 30, 40 years?” “TRY and make sure we stay in step with how the world is changing.” &#8230; <a href="http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Buying Physicians&#8217; Prescriptions in Cash or Kind: A Global (Dis)Order?</title>
		<link>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder</link>
		<comments>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/#comments</comments>
		<pubDate>Mon, 09 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[congressional]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[educating physicians]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globally]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[gut]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hidden]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[induce]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[investigation]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[lesser]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Council. of]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[much travelled]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[phenomenon]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[shun]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[wrenching]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2530</guid>
		<description><![CDATA[Recently a European business lobby reportedly raised its voice alleging pharma Multinational Corporations (MNCs) in China have been &#8216;unfairly targeted&#8217; by a string of investigations into bribery and price-fixing cases despite their generally ‘strong legal compliance’ and has suggested that China &#8230; <a href="http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Small Steps, yet Giant Leaps: In Pursuit of Affordable Medicines for All</title>
		<link>http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all</link>
		<comments>http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/#comments</comments>
		<pubDate>Mon, 01 Apr 2013 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Improving]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[leaps]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[SMS]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[steps]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2116</guid>
		<description><![CDATA[Since last few years, some small yet very significant steps are being taken, mostly by the respective Governments, in and outside India, to provide affordable healthcare in general and affordable medicines in particular, for all. It is well recognized that &#8230; <a href="http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ensuring ‘health outcomes’ based drugs prescriptions will be more beneficial for the patients in India than just ‘price control’ of drugs</title>
		<link>http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs</link>
		<comments>http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/#comments</comments>
		<pubDate>Thu, 18 Jun 2009 01:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[beneficial]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ensuring]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[just]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=857</guid>
		<description><![CDATA[Currently the global pharmaceutical market is undergoing a metamorphosis. The concept of ‘evidence-based medicine’ is gaining ground in the developed markets of the world, making the pharmaceutical companies generate requisite ‘health outcomes’ data using similar or equivalent products. Cost of &#8230; <a href="http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
